Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Beam Therapeutics Inc. (BEAM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient Consented in Phase 1/2 Trial of BEAM-201 in T-ALL/T-LL and Expected to be Dosed in The Third Quarter of 2023 Company to Accelerate Development of BEAM-302 for Treatment of AATD; Program Now Expected to be First In Vivo Liver Regulatory Filing in First Quarter of 2024 Well-Capitalized with $1.1B in Cash, Cash Equivalents and Marketable Securities at the End of the Second Quarter of 2023 CAMBRIDGE, Mass., August 8, 2023"
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/10/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amendment No. 2 to Sales Agreement, by and between Beam Therapeutics Inc. and Jefferies LLC",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to Beam Therapeutics Inc"
05/10/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives Multiple Sites Activated and Additional Patients Enrolled in BEACON Clinical Trial of BEAM-101 for Patients with Sickle Cell Disease Twenty-Year Industry Veteran, Gopi Shanker, Ph.D., Appointed as Chief Scientific Officer Well-Capitalized with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities at the End of the First Quarter of 2023 CAMBRIDGE, Mass., May 10, 2023"
02/28/2023 8-K Quarterly results
01/09/2023 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Beam Therapeutics Inc. Corporate Presentation",
"Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones"
11/07/2022 8-K Quarterly results
Docs: "Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1strategy Execution IND-enabling Studies Underway for BEAM-301 for Treatment of GSDIa BEAM-302 Nominated as Development Candidate for Treatment of Alpha-1 Antitrypsin Deficiency; Targeting Durable Gene Correction Designed to Address Both Lung and Liver Disease New Data Highlighting Enhanced Conditioning Approach for Hematologic Transplant to be Presented at ASH Ended Third Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities CAMBRIDGE, Mass., November 7, 2022 – Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines t..."
09/07/2022 8-K Other Events  Interactive Data
08/30/2022 8-K Other Events  Interactive Data
08/09/2022 8-K Quarterly results
08/01/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application CAMBRIDGE, Mass., August 1, 2022 –"
06/10/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "PRECISION GENETIC MEDICINES THROUGH BASE EDITING",
"Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM-301 Named as Fourth Development Candidate for the Treatment of Glycogen Storage Disease Type Ia Nomination of Two Additional Development Candidates Anticipated in 2022 Company to Present Pipeline and Business Updates at 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET. CAMBRIDGE, Mass., January 09, 2022 - Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines through base editing, today outlined anticipated 2022 milestones across its..."
11/08/2021 8-K Quarterly results
Docs: "Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Also Underway CAMBRIDGE, Mass., Nov. 8, 2021 -Beam Therapeutics Inc."
08/10/2021 8-K Quarterly results
Docs: "Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of IND-Enabling Studies for BEAM-201 CAMBRIDGE, Mass., Aug. 10, 2021 -Beam Therapeutics Inc."
07/07/2021 8-K Quarterly results
06/11/2021 8-K Quarterly results
05/24/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
04/23/2021 8-K Quarterly results
04/01/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
02/23/2021 8-K Quarterly results
01/19/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : January 16, 2021 Beam Therapeutics Inc. Delaware 001-39208 81-5238376 26 Landsdowne St. Cambridge, MA 02139 Registrant's telephone number, including area code: 327-8775 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencem...",
"Form of Purchase Agreement, among Beam Therapeutics Inc. and each purchaser party thereto",
"Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors"
01/12/2021 8-K Regulation FD Disclosure
01/12/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Beam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Candidate for Treatment of T-ALL; First Cell Therapy Featuring Four Simultaneous Genetic Edits; Demonstrates 96-99% On-target Editing and In Vivo Proof of Concept of Tumor Clearance"
08/12/2020 8-K Quarterly results
06/29/2020 8-K Quarterly results
05/12/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Beam Therapeutics Reports Additional Data at ASGCT Annual Meeting and First Quarter 2020 Financial Results Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In Vivo"
03/30/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 30, 2020 BEAM THERAPEUTICS INC. Delaware 001-39208 81-5238376 26 Landsdowne St. Cambridge, MA 02139 : 327-8775 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the...",
"Beam Therapeutics Reports Business Updates and Full Year 2019 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy